<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Erythroblastic and/or megakaryocytic <z:mpath ids='MPATH_589'>dysplasia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">EMD</z:e>) was evaluated in diagnostic bone marrow smears of 43 consecutively treated patients under 65 years with de novo <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) M0-M5 according to FAB criteria </plain></SENT>
<SENT sid="1" pm="."><plain>The evaluation was possible in 39 (91%) patients, i.e. in 32 of 34 patients with non-M3 <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> treated in the study UHKT-911 and seven of nine cases with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> M3 treated in other studies </plain></SENT>
<SENT sid="2" pm="."><plain>Among non-M3 <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> 15 patients were categorized without <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">EMD</z:e> and 17 cases with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">EMD</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Cytogenetic abnormalities of chromosome 5, 7, 3 or a complex karyotype were found in eight of 17 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">EMD</z:e> and in one of 15 cases without <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">EMD</z:e> (P = 0.018) </plain></SENT>
<SENT sid="4" pm="."><plain>Seven patients in each category exhibited a <z:mpath ids='MPATH_458'>normal</z:mpath> karyotype </plain></SENT>
<SENT sid="5" pm="."><plain>Classical induction therapy with three to four doses of <z:chebi fb="0" ids="41977">daunorubicin</z:chebi> 45 mg/m2 and standard doses of <z:chebi fb="1" ids="16040">cytosine</z:chebi> <z:chebi fb="0" ids="22601">arabinoside</z:chebi> (AraC) for 7 days lead to complete remission in 11 of 14 (78.6%) cases without <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">EMD</z:e> but only in four of 14 (28.6%) cases with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">EMD</z:e> (P = 0.021) </plain></SENT>
<SENT sid="6" pm="."><plain>High doses (2000 mg/m2 per 12-h x 10) of AraC plus <z:chebi fb="0" ids="41977">daunorubicin</z:chebi> induced complete remission in seven of 10 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">EMD</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">EMD</z:e> showed significantly worse overall survival (P = 0.03) with a median 13.5 months, while the median survival was estimated to 68.7 months in cases without <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">EMD</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>The dysplastic features of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">EMD</z:e>, karyotypes typical for <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), poor response to classical therapy and survival show a relation of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">EMD</z:e> to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> without <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">EMD</z:e> may represent a different biological favorable category </plain></SENT>
</text></document>